<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04153305</url>
  </required_header>
  <id_info>
    <org_study_id>ERNEST - FROM/O1- 2019</org_study_id>
    <nct_id>NCT04153305</nct_id>
  </id_info>
  <brief_title>European Registry for Myeloproliferative Neoplasms (MPNs) - Update of ERNEST Study</brief_title>
  <acronym>ERNEST</acronym>
  <official_title>European Registry for Myeloproliferative Neoplasms (MPNs) - Update of ERNEST Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione per la Ricerca Ospedale Maggiore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione per la Ricerca Ospedale Maggiore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Fondazione per la Ricerca Ospedale di Bergamo (FROM) decided to propose and promote the&#xD;
      completion of ERNEST registry: the aim of the project is to obtain up-to-date estimates of&#xD;
      clinical outcome of these patients in primary and secondary Myelofibrosis that have been&#xD;
      included in the 'original' ERNEST study. The last was conducted between 2012 and beginning of&#xD;
      2015 including 1292 patients with Myelofibrosis, but it was interrupted in 2015 because of&#xD;
      bankruptcy of the previous sponsor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Follow-up of patients already been registered in the ERNEST registry resulting alive and/or&#xD;
      in active surveillance at November 2014 (Blood 2014 124:1849) will be updated retrospectively&#xD;
      until December 2020. Data collection will be centralized at Fondazione per la Ricerca&#xD;
      Ospedale di Bergamo (FROM), and performed by a web-based and Electronic Data Capture (EDC)&#xD;
      system through ad hoc electronic case report forms (e-CRFs). The e-CRFs system will be&#xD;
      pre-filled with pre-existing data collected from cases already entered in the registry.&#xD;
      Information on therapies received and outcome events occurred (in term of death, evolution to&#xD;
      acute leukemia, secondary cancer and cardiovascular complications) until December 2020 will&#xD;
      be recorded by authorized participating investigators.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 8, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of death</measure>
    <time_frame>18 years</time_frame>
    <description>Overall Survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with evolution to acute leukemia (AL)</measure>
    <time_frame>18 years</time_frame>
    <description>Occurrence of AL from diagnosis to last observation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with secondary tumor (ST)</measure>
    <time_frame>18 years</time_frame>
    <description>Occurrence of ST from diagnosis to last observation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with cardiovascular (CV) complications</measure>
    <time_frame>18 years</time_frame>
    <description>Occurrence of events from diagnosis to last observation</description>
  </secondary_outcome>
  <enrollment type="Anticipated">578</enrollment>
  <condition>Myelofibrosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients aged 18 years old or more, with diagnosis of Primary Myelofibrosis (PMF),&#xD;
        Post-Polycythemia Vera Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia&#xD;
        Myelofibrosis (PET-MF) performed according WHO 2001 or WHO 2008, between 2001 and 2012.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  previous registration in the ERNEST registry (2012 - 2014)&#xD;
&#xD;
          -  diagnosis of MF performed between January 2001 and 2012 December&#xD;
&#xD;
          -  Signed informed consent to continue participation in the registry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tiziano Barbui, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fondazione per la Ricerca Ospedale di Bergamo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AOU Careggi</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UOC Ematologia, ASST Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <state>Lombardia</state>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione Ematologia, Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <state>Lombardia</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia, Ospedale di Circolo e Fondazione Macchi Varese</name>
      <address>
        <city>Varese</city>
        <state>Lombardia</state>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Cl√≠nic de Barcelona</name>
      <address>
        <city>Barcellona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center is Hematology Section, Uddevalla Hospital</name>
      <address>
        <city>Uddevalla</city>
        <zip>451 53</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Spain</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 4, 2019</study_first_submitted>
  <study_first_submitted_qc>November 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2019</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>survival</keyword>
  <keyword>acute leukemia</keyword>
  <keyword>second cancer</keyword>
  <keyword>cardiovascular complication</keyword>
  <keyword>update</keyword>
  <keyword>disease management</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

